Abstract: The present invention relates to sulfate-free aqueous personal care composition comprising from about 0.2 pbw to about 15 pbw of a derivatized cationic guar comprising cationic substituent groups and non ionic substituent groups, at least 0.05 pbw of an oil and from about 2 pbw to about 20 pbw of a surfactant system comprising at least one lauramphoacetate, and one sulfosuccinate. It is also directed toward the use of such a composition for washing keratin substrates, in particular the hair or the scalp.

Abstract: Compositions and methods for reshaping keratin-rich substrates while forming adherent flexible films contain emulsified or soluble mixtures of silanols and hemiaminals or the reaction products of silanols and hemiaminals including silylated hemiaminals. A method for treating split-ends in hair is also described.

Abstract: The invention relates to a solid composition for making up and/or caring for the skin and/or the lips, in wand form, comprising: sunflower wax; candelilla wax; at least one triglyceride chosen from triglycerides of caprylic acid, of capric acid, of caprylic/capric acid, or mixtures thereof; at least one plant oil with the exception of castor oil; castor oil, if it is present, not exceeding a content of 5% by weight relative to the total weight of the composition; at least one polyester derived from the condensation of a linear or branched C6-C10 dicarboxylic acid and of an ester of diglycerol and of optionally hydroxylated, linear or branched C6-C20 monocarboxylic acids. The invention also relates to a process for making up and/or caring for the skin and/or the lips, which consists in applying said composition.

Abstract: The present invention relates to a use of a fermentation product of Lacticaseibacillus casei of cannabis stems and an extract thereof for ameliorating skin wrinkles caused by photoaging, and to an anti-wrinkle cosmetic composition or pharmaceutical composition including the fermentation product.

Abstract: The invention relates to a cosmetic composition comprising at least one birch sap extract, and at least one extract chosen from an aqueous extract of beech buds and an oily extract of beech buds, and at least one cosmetically acceptable vehicle.

Abstract: The systems and methods of the disclosure provide, inter alia, consumer products, e.g., finished consumer products that may be considered to be “biome-friendly” or “biome-compatible.” The systems and methods of the disclosure may provide for use of consumer products, e.g., finished consumer products, that may be used in combination with bacteria, e.g., non-pathogenic bacteria, e.g., ammonia oxidizing bacteria, which may be used in the form of a preparation or composition to be applied to a surface and/or to be used by a subject.

Abstract: Provided are methods of preparing skin for surgery to reduce a risk of infection by bacteria present in skin pores. Also provided are kits for performing such methods. The methods include exposing the bacteria by applying and then removing a first adhesive member from the skin, and then applying an antibacterial agent to the skin.

Abstract: Embodiments of the application are directed toward a liquid topical sinus therapy for a patient, comprising a medicated formulation including at least one medication, and a device for delivering the medicated formulation to the patient's nostrils, nasal passages, or sinuses. The medicated formulation may include drugs selected from the group consisting of corticosteroids, antibiotics, antifungals, antihistamines as well as herbal and alternative medications. Dosage forms include powders, tablets and gels which facilitate clinical testing and enable patient compliance.

Abstract: Injectable compositions and methods of use are discussed. The injectable composition may include at least one biocompatible material chosen from polyethylene glycol (PEG), alginate, methylcellulose, carboxymethylcellulose, hydroxypropylmethylcellulose, chitosan, carboxymethylchitosan, laponite, gelatin, xanthan gum, or a combination thereof, and a biocompatible salt solution. The composition may be formulated to form a gel in submucosal tissue to separate tissue layers. The viscosity of the composition may decrease by at least 50% at 37° C. within 24 hours.

Abstract: Compositions and methods are provided for the use of hydrogel compositions to anchor a device, or therapeutic entity, to a specific portion of the GI tract. In some embodiments a biodegradable hydrogel is injected into the intestinal wall to narrow the lumen, such that a device can be confined to that specific segment of the intestine for a desired period of time. In some embodiments the device is an in situ expander for distraction enterogenesis of the intestine.

Abstract: An orodispersible powder composition including an active pharmaceutical ingredient and a ternary synergistic combination of sodium citrate, citric acid and sucralose. It also relates to a stick pack and a tablet including such orodispersible powder composition, and their use as a medicament.

Abstract: In some aspects, the present disclosure pertains to a radiopaque, reactive polymer comprising one or more hydrophilic polymer segments having a plurality of hydrophilic polymer segment ends, a plurality of iodinated cyclic anhydride residues covalently linked to the plurality of hydrophilic polymer segment ends, and a plurality of reactive moieties covalently linked to the iodinated cyclic anhydride residues. In some aspects, the present disclosure pertains to a system for forming a hydrogel composition that comprises (a) a nucleophilic compound and (b) such a radiopaque, reactive polymer. In some aspects, the present disclosure pertains to a method of treatment comprising administering to a subject a mixture that comprises (a) a nucleophilic compound and (b) such a radiopaque, reactive polymer under conditions such that the nucleophilic compound and the radiopaque, reactive polymer crosslink after administration.

Abstract: A method of preparing a gelling agent, the gelling agent obtained thereby, and the use of said gelling agent The present invention relates to a method of obtaining a novel gelling agent. Said method comprises adding ethylcellulose, to a mixture of propyleneglycol laurate and propyleneglycol isostearate at a temperature of between 90° C. and 110° C. The method according to the invention provides a simpler, less energy consuming, cheaper and easier way of obtaining a substantially gelling agent which can be used for manufacturing an oleogel and/or a bigel, for cosmetic and/or pharmaceutical use.

Abstract: There is disclosed a liquid resin extended-release oral naltrexone formulation suspension comprising from about 1.0 mg/ml to about 10.0 mg/ml naltrexone in a resin, wherein no more than 30% of the total naltrexone dose administered is released within one hour and wherein no more than 60% of the total naltrexone dose administered is released within two hours. Specifically, there is disclosed a method for treating a child with an autism-type disorder with approximately a teaspoon (about 5 ml) of a liquid resin extended-release oral naltrexone formulation suspension comprising from about 1.0 mg/ml to about 10.0 mg/ml naltrexone in a resin, wherein no more than 30% of the total naltrexone dose administered is released within one hour and wherein no more than 60% of the total naltrexone dose administered is released within two hours.

Abstract: A composition comprising nanoparticles comprising benzoyl peroxide, benzyl chloride and/or benzalkonium chloride and a method using this composition to kill or inhibit the growth of microorganisms including bacteria and viruses.

Abstract: This invention provides methods of treating neurologic disorders including, but not limited to, synucleinopathic disorders (including Parkinson's Disease), Alzheimer's Disease, Amyotrophic Lateral Sclerosis (ALS) disease and Huntington's disease. The methods include delivery into neuronal cells of antibody or antibody fragment(s), or nucleic acids encoding intrabodies, such as single domain antibodies and single chain Fv antibody fragments against proteins associated with such neurologic disorders, suitably using a liposomal complex that crosses the blood brain barrier and can deliver the payload into neuronal cells. This invention also provides methods wherein a delivered nucleic acid encodes a protein which is a nanobody targeted to a neuronal postsynaptic scaffolding protein Homer1 that is present at partially overlapping sets of excitatory synapses, and is associated with Fragile X Syndrome (FXS) and Deafness, Autosomal Dominant 68 (DFNA68).

Abstract: The invention provides a cationic lipid, a lipid membrane structure containing same, and use thereof. The cationic lipid is represented by the formula (1) wherein R1a, R1b, R2a, R2b, R3a, R3b, Xa, Xb, Ya, Yb, Za, and Zb are as defined in the specification.

Abstract: Dry suspension granules for dry suspension, including the dry suspension made of the said dry suspension granules, and preparation method thereof are provided. Such-The dry suspension granules contain anionic gel and cationic polymer. The weight ratio of the anionic gel and the cationic polymer is (0.5-50):1.

Abstract: A composition including an amphiphilic compound capable of self-assembling into liquid crystalline particles and a statin for systemic administration via oral mucosa. A method of lowering blood cholesterol levels in a subject comprising administering the self-assembling liquid crystalline particles and statin via oral mucosa. Preferred dosage forms result in prolonged release of the statin.

Abstract: Disclosed are novel pharmaceutical compositions comprising gepotidacin, such as gepotidacin mesylate dihydrate, gepotidacin mesylate anhydrate or gepotidacin anhydrate. The present disclosure also provides methods for making the pharmaceutical composition comprising gepotidacin, and methods of treating bacterial infections using such pharmaceutical composition.

Abstract: Described herein are synthetic progestogens, such as 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.

Abstract: Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.

Abstract: The present invention relates to pharmaceutical compositions of ozanimod or a pharmaceutically acceptable salt thereof. In particular, the invention relates to pharmaceutical compositions of ozanimod or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable excipients, and optionally one or more controlled release substances. The invention also relates to processes for the preparation of such compositions and use thereof for treatment of inflammatory bowel disease.

Abstract: The invention describes a core shell microcapsule wherein the capsule shell is an interfacial copolymer formed of a modified polysaccharide free radical cross-linked with a multifunctional (meth)acrylate. The polysaccharide is hydrophobically modified with an adduct containing at least one unsaturated bond. The modification imparts hydrophobic character to the polysaccharide to act as an emulsifier, driving the modified polysaccharide to an oil-water interface of an encapsulation emulsion described, and creates an active bonding site for free-radical polymerization between the polysaccharide and multifunctional (meth)acrylate, thereby forming a microcapsule shell surrounding the core material.

Abstract: The present disclosure relates to novel compounds, methods, and cell-targeting formulations, e.g., a lipid nanoparticle (LNP) for targeted delivery to a tissue or a cell type. The compound and formulation provided herein are designed to have a targeting moiety configured to provide selective delivery features for the formulation and a lipid tail for being incorporated into the bilayer membrane of the formed lipid nanoparticle.

Abstract: The present disclosure provides novel compounds, methods, and cell targeting mRNA vaccine formulations for targeted delivery, such as delivery to dendritic cells. The compound and formulation provided herein are designed to have a targeting moiety configured to provide selective delivery features specific for dendritic cells and a lipid tail for incorporated into the bilayer membrane of the formed lipid nanoparticle.

Abstract: The present disclosure includes, among other things, lipids, compositions, and methods useful for delivering a polynucleotide or oligonucleotide, e.g., viral genome.

Abstract: Nanoparticle compositions described herein comprise combinations of prodrugs of therapeutic agents that achieve enhanced therapeutic effects as compared to those observed when combinations of free forms of these therapeutic agents are administered.

Abstract: The present invention relates to a kit for preparing nanoparticles containing a drug and, more specifically, to a kit for preparing drug-containing nanoparticles, the kit enabling a drug to be easily contained in nanoparticles by simple mixing only, preferably, in a specific weight ratio, the drug and nanoparticles containing a cationic compound and a polylactate, as kit constituent components comprising no amphiphilic polymers, and being designed to enable the efficiency of drug delivery into cells to be greater than that of a kit comprising an amphiphilic polymer.

Abstract: The present disclosure relates to nanoparticles comprising a payload and a conjugate having the structure of formula (I):

Abstract: Provided are lipid nanoparticle compositions, and processes for their preparation, which are useful for the delivery of therapeutic or prophylactic agents to airway epithelium in patients.

Abstract: A patch includes an adhesive layer that includes (a) a drug, (b) a thermoplastic elastomer, and (c) non-volatile hydrocarbon oil having a kinematic viscosity of 60 mm2/s or less at 40° C. The (a) drug includes (i) an amino group that may have a substituent, and (ii) at least one functional group selected from the group consisting of an ester group, an amide group, an ether group, a thioether group, and an amino group different from the (i) amino group, all of which may have a substituent. The (a) has a structure, in which the (i) amino group, and the (ii) at least one functional group are bonded via a C1-C3 hydrocarbon chain. The number of hydroxyl groups per molecule of the (a) is 4 or less. An amount of the (c) is 230 parts by mass or less relative to 100 parts by mass of the (b).

Abstract: The invention relates to a composition and method for treating infections, preventing infections, reducing the likelihood of infections, or reducing the severity of infections in the sinonasal tract, by topically administering a composition comprising glycerol. The invention also relates to a method for supporting a healthy sinonasal microbiome, comprising topically administering a composition comprising glycerol. The invention also relates to a method for promoting the growth of commensal bacteria and inhibiting the growth of pathogenic bacteria in the sinonasal tract, comprising topically administering a composition comprising glycerol.

Abstract: Disclosed herein are compositions comprising a GLP-1R agonist composition, a DPP-4 inhibitor composition, or a combination of both. The description contained herein describes methods for inducing weight loss and/or boosting satiety in a subject. The compositions described herein may be formulated for oral administration, and in some embodiments, may further comprise enteric or pH-responsive coatings.

Abstract: The present disclosure is related to a composition and method for the treatment and/or prevention of skin and/or mucosal conditions resulting from microbial overgrowth, imbalance, or infections. The method comprises administering a composition to a subject that comprises in particular carvacrol and Terpinen-4-ol in amounts and mutual ratios to maintain a balance between beneficial, commensal microorganisms and non-beneficial, opportunistic pathogenic microorganisms.

Abstract: A honokiol liposome transdermal gel includes by weight percentage: 1-40% honokiol liposome and 10-85% gel matrix. The honokiol liposome comprises phospholipid, honokiol, cholesterol, and polyethylene glycol or pegylated phospholipid, in a weight ratio of 2-10:1:0.3-0.6:0.1-0.3; and the gel matrix is poloxamer. The invention achieves an encapsulation efficiency of honokiol greater than 90%, the honokiol liposome transdermal gel has high transdermal efficiency, rapid and sustained absorption, and high stability, and shows good therapeutic effects for skin diseases.

Abstract: Compositions of dimethyl trisulfide (DMTS) suitable for use for treatment of cyanide intoxication. The compositions show particularly useful stability such that the DMTS remains stable for therapeutic use at the identified time periods. The compositions are therefore particularly suitable for use in autoinjectors.

Abstract: Provided herein are compounds (e.g., compounds of Formula (I) and Formula (II), that modulate HCN channels, intermembrane proteins that serve as nonselective voltage-gated cation channels in the plasma membranes of heart and brain cells. Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating HCN-related disorders (e.g., pain) with the compounds in a subject, by administering the compounds and/or compositions described herein.

Abstract: The present invention provides a method for safe and efficacious administration of esketamine.

Abstract: Provided herein are compounds of Formula (I), Formula (I-A), Formula (I-B), or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), Formula (I-A), Formula (I-B) or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I), Formula (I-A), Formula (I-B) or pharmaceutically acceptable salt thereof. The current invention reports compounds to reduce REM sleep and/or non-REM sleep in a subject which can be effective in treating diseases or disorder where sleep is dysregulated. The methods of the disclosure include methods of treating sleep dysfunction, sleep disorder, stress related disorders, neuropsychiatric diseases, neurological conditions and/or neurodevelopmental disorders, using the compound of Formula (I), Formula (I-A), and/or Formula (I-B).

Abstract: A ready-to-administer antioxidant free phenylephrine compositions has improved stability and is optionally free of metal chelating agents. Contemplated compositions are preferably packaged into a flexible polymer bag and maintain degradation of the phenylephrine at remarkably low levels. even over extended storage periods.

Abstract: The present disclosure provides sublingual epinephrine tablets and methods of treating anaphylaxis, methods for concomitant therapy during a cardiac event, treating hypoglycemia, and prophylaxis for immunotherapy, using sublingual epinephrine tablets.

Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.

Abstract: A formulation comprising TML-6 or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof in an amorphous form, and one or more excipients,

Abstract: Compounds represented by Formula I: wherein A, B, W, V, Z, Ra, Rb, n and m are as defined in the instant specification, or by Formula Ia, Ib, III, IV or V, as defined in the instant specification, and uses thereof in modulating an activity of a voltage-dependent potassium channel and/or a TRPV1 channel and in treating a medical condition associated with an activity of these channels, such as medical conditions associated with neuronal hyper-excitability, are provided.

Abstract: The present invention relates to therapeutic patches, particularly to soluble patches that adhere to mucosal membranes (e.g. in the oral cavity) to deliver analgesic (e.g. local anaesthetic) compounds (e.g. lidocaine) to sites of pain. In particular, the invention provides a mucoadhesive patch comprising a pharmaceutically acceptable soluble film and mesoporous microparticles loaded with an analgesic agent.

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract: Autism Spectrum Disorders (ASD) are neurodevelopmental disorders whose diagnosis relies on deficient social interaction and communication together with repetitive behavior. To date, no pharmacological treatment has been approved that ameliorates social behavior in patients with ASD. Based on the excitation/inhibition imbalance theory of autism, the Inventors hypothesized that bromide ions, long used as an antiepileptic medication, could relieve core symptoms of ASD. They evaluated the effects of chronic sodium bromide (NaBr) administration on autistic-like symptoms in three genetic mouse models of autism: Oprm1?/?, Fmr1?/? and Shank3?ex13-16?/? mice. They showed that chronic NaBr treatment relieved autistic-like behaviors in these three models. In Oprm1?/? mice, these beneficial effects were superior to those of chronic bumetanide administration.

Abstract: Disclosed herein are mitofusin inhibitors which are capable of inducing mitochondrial fission, decreasing mitochondrial respiration, TCA metabolism, and inducing mitochondrial outer membrane permeabilization that leads to caspase activation and DNA damage signaling. Also disclosed are methods of treating diseases or conditions associated with imbalanced mitochondrial dynamics.

Abstract: The present disclosure relates to the field of treatment of an orphan disease, in particular treatment of vascular Ehlers-Danlos syndrome (vEDS). More specifically, the present disclosure relates to novel up-titration dosage regimens (e.g., escalating dosage regimens) effective for treating vEDS patients with celiprolol.